Last reviewed · How we verify
Alogliptin and glyburide
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while glyburide stimulates pancreatic beta cells to release insulin.
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while glyburide stimulates pancreatic beta cells to release insulin. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Alogliptin and glyburide |
|---|---|
| Also known as | alogliptin, SYR110322, SYR-322 |
| Sponsor | Takeda |
| Drug class | DPP-4 inhibitor + sulfonylurea combination |
| Target | DPP-4 (dipeptidyl peptidase-4) and sulfonylurea receptor (SUR1) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination of two oral antidiabetic agents with complementary mechanisms. Alogliptin, a DPP-4 inhibitor, prolongs the action of incretin hormones (GLP-1 and GIP) to enhance glucose-dependent insulin secretion and suppress glucagon. Glyburide, a meglitinide-class sulfonylurea, directly stimulates insulin release from pancreatic beta cells. Together, they provide dual glucose-lowering effects for type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Diarrhea
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alogliptin and glyburide CI brief — competitive landscape report
- Alogliptin and glyburide updates RSS · CI watch RSS
- Takeda portfolio CI